ASX Announcement
28 March 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan to present at TSN ASX Gems Conference

Optiscan Imaging Limited (ASX:OIL) ('**Optiscan**' or the '**Company**') is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by CEO and Managing Director, Dr Camile Farah who will present at The Stock Network's ASX Gems Conference.

Event	ASX Gems Investment Conference
Date	Friday 28 March
Time	11am – 1pm AEDT
Format	Live stream from The Stock Network's YouTube channel
Register	The event is free and investors can register online to view the presentation at: https://www.eventbrite.com/e/the-stock-networks-asx-gems-conference-tickets-1298761062299?aff=oddtdtcreator

The event will livestream from 11am – 1pm AEDT and can be accessed at any time on The Stock Network's YouTube. A copy of Optiscan's investor presentation will be lodged on the ASX platform prior to commencement of the conference.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.